Treatment of CML, including ABL TKI resistance, using a regimen combining the current standard of care, asciminib, and VK2 appears to be a viable method, although more preclinical and clinical testing is needed. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.